 2017 saw the World Health Organization name Abormonini as one of its top priority pathogens requiring new treatments, with only two antibiotics left as last resort options. Vaccines against bacteria have been successful in reducing disease burden and addressing antimicrobial resistance, such as hemophilus influenza type B. Several potential vaccine candidates for Abormonini were identified, but a licensed vaccine is not yet available. Challenges in vaccine development against Abormonini are discussed, along with promising approaches to improve the process. This article was authored by Nausia Matt Rahim, Hyen Lee, Ulrich Strych, and others.